IRB Letter

IRB Letter.pdf

Evaluation of the Food and Drug Administration’s Point-of-Sale Campaign

IRB Letter

OMB: 0910-0851

Document [pdf]
Download: pdf | pdf
IRB ID Number: 14230
Office of Research Protection

Institutional Review Board Notice of Approval
Federalwide Assurance No. 3331
Title of Study: Point of Sale Intervention for Tobacco Evaluation (POSITEv)
RTI Project Number: 0213772.003.001.005 RTI Proposal Number (if no Project Number):
Project Leader: Matthew Farrelly
Project Team Member Contact (if different from Project Leader): Lauren Dutra
Source of Funding for this Study: FDA
Date Submitted to IRB: October 26, 2017
Level of Review (check one):
Full , IRB Meeting Date:
Expedited , category: 7: Behavioral - surveys, focus groups, etc.

Type of Review (check one):
Preliminary review (For DHHS grants where RTI is prime, the grant application/contract proposal and protocol
submitted to the IRB are in concordance (45 CFR 46.103(f)). Do not involve human subjects or data until
pretest or full study is approved.)
Amendment, describe:
Add study site(s):
Pretest/Pilot Test:
Renewal
Full Implementation
Study Closure
IRB Approval of Special Conditions (check all that apply to this review):
Waiver of Signed Informed Consent/Parental Permission
Waiver of elements of Informed Consent or requirement for Informed Consent/Parental Permission
Participation of Pregnant Women (Worksheet B submitted by project team)
Participation of Prisoners (Worksheet C submitted by project team)
Participation of Prisoners in DHHS-funded studies (OHRP acknowledgement required)
Participation of Minors (Worksheet D submitted by project team)
IRB Agreement of Nonsignificant Risk Device Study Determination
HIPAA Waiver of Authorization
Please note the following requirements:
• If unexpected problems or adverse events occur, the project team must notify the IRB.
• If there are changes in study procedures or protocol or any data collection materials (brochures, letters,
questionnaires, etc.) the project team must notify the IRB before they are implemented.
• The project team is required to apply for continuing review as long as the study is active, which includes
participation of human subjects or possession of human data or specimens.

Expiration Date of IRB Approval: October 26, 2018
(No human subjects research can occur after this date without continuing review and approval.)

October 26, 2017
Signature - IRB Member or Chair

Date of IRB Approval

Jamia Bachrach, JD
Name - IRB Member or Chair (print or type)
Copy sent to project leader on: October 26, 2017
Entered into MIS
OHRP acknowledgement received for participation of prisoners in DHHS-funded studies on:

Office of Research Protection, Institutional Review Board
3040 Cornwallis Road, Research Triangle Park, NC 27709-2194, USA
Telephone: 919-316-3358 Fax: 919-316-3897 orpe@rti.org


File Typeapplication/pdf
AuthorAnna Weaver
File Modified2017-10-27
File Created2017-10-26

© 2024 OMB.report | Privacy Policy